TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 31723767
Drug: Idelalisib in
Normalized name: Product containing idelalisib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idelalisib in combination with both Rituximab and Bendamustine (IBR)
Study: 31724813
Drug: Talazoparib (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talazoparib (600 µg/m) in combination with low-dose temozolomide (TMZ)
Study: 31725015
Drug: BET inhibitor
Normalized name: BET INHIBITOR TEN-010
DrugBank: RO-6870810 (DB15151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BET inhibitor apabetalone
Study: 31725459
Drug: Antiviral therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral therapy for 78 weeks
Study: 31726422
Drug: Proprotein convertase
Normalized name: Proprotein convertase 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i)
Study: 31727136
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of suPAR and CRP
Study: 31729626
Drug: Peficitinib (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peficitinib (150 mg single oral dose)
Study: 31730164
Drug: IV administration
Normalized name: IV Administration Set
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV administration of ertapenem (1 g once daily)
Study: 31730497
Drug: Conventional synthetic
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs) including methotrexate (MTX)
Study: 31732655
Drug: Increased prescription
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased prescription of P2Y
Study: 31733180
Drug: Rivaroxaban at
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban at a dose of 10 mg daily (with aspirin at a dose of 75 to 100 mg daily for the first 3 months)
Study: 31733180
Drug: Antiplatelet group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiplatelet group (aspirin at a dose of 75 to 100 mg daily with clopidogrel at a dose of 75 mg daily for the first 3 months)
Study: 31734820
Drug: Dotinurad 1
Normalized name: Dotinurad
DrugBank: Dotinurad (DB16145)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Dotinurad 1 mg for 7 days
Study: 31734820
Drug: Topiroxostat 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topiroxostat 80 mg (concomitant use with Dotinurad)
Study: 31734832
Drug: RO6839921 (14-120
Approvals — FDA: no, EMA: no, PMDA: no
Description: RO6839921 (14-120 mg AP)
Study: 31735436
Drug: VKAs (warfarin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: VKAs (warfarin, acenocoumarol)
Study: 31738180
Drug: Artificial intelligence-driven
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence-driven monitoring solution with automatic alerts
Study: 31738180
Drug: Artificial intelligence-driven
Normalized name: Intelence
DrugBank: Etravirine (DB06414)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Artificial intelligence-driven monitoring solution
Study: 31738181
Drug: Early AKI
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early AKI (defined by an increase in serum creatinine >0.3 mg/dl or urine output <1 ml/kg per hour on postnatal days 2-7)
Study: 31738425
Drug: larotrectinib (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: larotrectinib (20 mg/kg twice daily)
Study: 31740479
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone therapy in transgender men (TM)
Study: 31740479
Drug: Gender-affirming hormone
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gender-affirming hormone therapy in transgender women (TW)
Study: 31741786
Drug: Muscular Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Muscular Group (MG)
Study: 31742564
Drug: Lower vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower vitamin D group (<25 ng/ml), n=22
Study: 31742564
Drug: Higher vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher vitamin D group (≥25 ng/ml), n=21
Study: 31744781
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRI) mono-class therapy
Study: 31744781
Drug: Antipsychotic-containing regimens
Normalized name: Anacin Aspirin Regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antipsychotic-containing regimens
Study: 31744895
Drug: ERK Inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: ERK Inhibitor LY3214996
Study: 31749854
Drug: Diffusing alpha
Normalized name: alpha tocopherol
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diffusing alpha emitters radiation therapy (DaRT) applied to one lesion.
Study: 31750307
Drug: Three different
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three different exercise strategies, details on dosage and duration not available
Study: 31750837
Drug: Standard self-monitoring
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard self-monitoring app (cognitive behavioral therapy-based)
Study: 31752504
Drug: Extended follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended follow-up intervals for INR monitoring, specific dosage and duration not available
Study: 31752504
Drug: Standard follow-up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard follow-up intervals for INR monitoring, specific dosage and duration not available
Study: 31752752
Drug: Oral metformin
Normalized name: metformin Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral metformin at doses up to 3000 mg per day for 3 months
Study: 31752951
Drug: Dual-mobility cup
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual-mobility cup and cementless triple-taper femoral stem combination
Study: 31752976
Drug: Delay to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delay to appropriate antimicrobial treatment
Study: 31752976
Drug: Prolonged antimicrobial
Normalized name: GAUZE,ANTIMICROBIAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged antimicrobial therapy (>7 days)
Study: 31753019
Drug: Chemotherapy combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy combined with anti-BTLA antibody
Study: 31753029
Drug: Atezolizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (15 mg/kg every 3 weeks for patients < 18 years; 1200 mg every 3 weeks for patients ≥ 18 years)
Study: 31756197
Drug: Delayed antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed antibiotic prescription
Study: 31758682
Drug: DAAO method
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAO method with phenylalanine intake of 15 mg · kg-1 · d-1 during early pregnancy
Study: 31758682
Drug: DAAO method
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Study: 31758682
Drug: IAAO method
Approvals — FDA: no, EMA: no, PMDA: no
Description: IAAO method with phenylalanine intake of 21 mg · kg-1 · d-1 during late pregnancy
Study: 31760835
Drug: 7 +
Normalized name: menaquinone 7
DrugBank: Menaquinone 7 (DB13075)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 + 3/5 + 2 chemotherapy
Study: 31760881
Drug: Treatment Satisfaction
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment Satisfaction Questionnaire, 9 items (TSQM-9)
Study: 31760881
Drug: Morisky Medication-Taking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Morisky Medication-Taking Adherence Scale (MMAS-4)
Study: 31763491
Drug: 36-ingredient micronutrient
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36-ingredient micronutrient supplement
Study: 31764746
Drug: Low-molecular-weight (LMW)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-molecular-weight (LMW) heparin plus aspirin (n=93)
Study: 31764746
Drug: Aspirin alone
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin alone (n=94)
Study: 31767018
Drug: Adenosine stress
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine stress (140 microg/kg/min infusion)
Study: 31767018
Drug: Rest (following
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rest (following intravenous contrast bolus 0.05 mmol/kg, gadobutrol)
Study: 31767463
Drug: VAX-ID® intradermal
Approvals — FDA: no, EMA: no, PMDA: no
Description: VAX-ID® intradermal injection technique
Study: 31767533
Drug: Very-accelerated partial
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Very-accelerated partial breast irradiation (vAPBI) using single fraction of multicatheter interstitial high-dose rate brachytherapy (MIB) at a dose of 16 Gy.
Study: 31767578
Drug: Polymorphisms of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polymorphisms of genes related to vitamin D metabolism and transportation
Study: 31767591
Drug: Multicomponent preoperative
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multicomponent preoperative and intraoperative intervention including systematic information, preoperative screening, nutrient supplementation, physical exercise, medication review, blood management, carbohydrate loading, orientation aids, and geriatric anaesthesia concept
Study: 31768261
Drug: Individualized follow-up
Normalized name: Q-Up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individualized follow-up through a smartphone application (app) on a weekly basis for one year.
Study: 31768262
Drug: 150,000 IU
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150,000 IU loading dose vitamin D
Study: 31769793
Drug: GSK2838232 (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (20 mg) with cobicistat 150 mg
Study: 31769793
Drug: GSK2838232 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (50 mg) with cobicistat 150 mg
Study: 31769793
Drug: GSK2838232 (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (100 mg) with cobicistat 150 mg
Study: 31769793
Drug: GSK2838232 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (200 mg) with cobicistat 150 mg
Study: 31769793
Drug: GSK2838232 (≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK2838232 (≥50 mg) with cobicistat 150 mg
Study: 31770437
Drug: BST-236 (aspacytarabine)
Normalized name: Aspacytarabine
DrugBank: Aspacytarabine (DB17226)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BST-236 (aspacytarabine) administered intravenously once daily over 60 minutes for 6 consecutive days at doses ranging from 0.3 to 6 g/m2 per day.
Study: 31770616
Drug: Genotype CC
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Genotype CC of rs1333049
Study: 31771630
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota composition in AS patients with increased fecal calprotectin (≥ 200 mg/kg, n=36)
Study: 31771630
Drug: Fecal microbiota
Normalized name: Fecal Microbiota
DrugBank: Fecal microbiota (DB17743)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fecal microbiota composition in AS patients with normal fecal calprotectin (≤ 50 mg/kg, n=57)
Study: 31772121
Drug: First-line HER2-targeted
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: First-line HER2-targeted therapy, chemotherapy, and sequential endocrine therapy
Study: 31772517
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy (MT)
Study: 31772517
Drug: Medication Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication Therapy (MT) (after PSM)
Study: 31772605
Drug: Perioperative continuation
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative continuation of statin therapy (CS group)
Study: 31772605
Drug: No statin
Approvals — FDA: no, EMA: no, PMDA: no
Description: No statin therapy (DS group)
Study: 31772766
Drug: Subretinal injection
Normalized name: LUXTURNA Suspension for Subretinal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subretinal injection of ranibizumab after vitrectomy with ILM peeling
Study: 31772984
Drug: Local hyperthermia
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local hyperthermia at 39°C to 43°C delivered using radiofrequency waves at 100 Mhz once a week after proton therapy.
Study: 31772984
Drug: Proton irradiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Proton irradiation at a dose of 70 to 72 Gy delivered at 2.0 Gy per fraction daily for 7 weeks.
Study: 31772984
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of local hyperthermia and proton irradiation.
Study: 31773439
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and weekly paclitaxel therapy
Study: 31774125
Drug: Fasting insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Fasting insulin and HOMA-IR
Study: 31774522
Drug: Gemcitabine (1200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1200 mg/m2, later amended to 1000 mg/m2 on days 1 and 8 every 3 weeks), plus trastuzumab (8-mg/kg loading dose, then 6 mg/kg), and pertuzumab (840-mg loading dose, then 420 mg) once every 3 weeks.
Study: 31774957
Drug: Low C-PTP
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low C-PTP and d-dimer <1000 ng/mL
Study: 31774957
Drug: Moderate C-PTP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate C-PTP and d-dimer <500 ng/mL
Study: 31774957
Drug: d-dimer level
Normalized name: dimer dilinoleyl dimer dilinoleate
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-dimer level 500 to 999 ng/mL
Study: 31774957
Drug: No diagnosis
Approvals — FDA: no, EMA: no, PMDA: no
Description: No diagnosis of pulmonary embolism and no anticoagulant therapy
Study: 31774957
Drug: Diagnostic strategy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diagnostic strategy with low C-PTP and d-dimer <1000 ng/mL
Study: 31774957
Drug: Alternative strategy
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alternative strategy with low C-PTP and d-dimer <500 ng/mL
Study: 31775667
Drug: Grade 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Grade 3 to 5 chemotherapy-related toxicities
Study: 31775677
Drug: Mifepristone (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mifepristone (600 mg) followed by misoprostol (400 μg, two doses 4 hrs apart)
Study: 31775677
Drug: Misoprostol alone
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Misoprostol alone (400 μg, two doses 4 hrs apart)
Study: 31776631
Drug: Chemokine receptor-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemokine receptor-4 targeted PET/CT
Study: 31776899
Drug: INC280 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: INC280 (300 mg twice daily) + buparlisib (80 mg once daily)
Study: 31776899
Drug: INC280 (monotherapy)
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: INC280 (monotherapy)
Study: 31778074
Drug: Crizotinib (ALK,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crizotinib (ALK, MET & ROS1 inhibitor)
Study: 31778267
Drug: Capmatinib 600
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 600 mg bid capsules
Study: 31778267
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid tablets
Study: 31778267
Drug: Capmatinib 200
Normalized name: capmatinib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capmatinib 200 mg bid, 250 mg bid, and 450 mg bid capsules
Study: 31778267
Drug: Capmatinib 400
Normalized name: CAPMATINIB
DrugBank: Capmatinib (DB11791)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capmatinib 400 mg bid tablets/600 mg bid capsules
Study: 31778281
Drug: Pain EASE
Normalized name: Pain Ease Mist
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pain EASE program (internet-delivered self-management program based on cognitive behavioral therapy)
Study: 31778798
Drug: Ceritinib (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceritinib (750 mg/day, fasted)
Study: 31780140
Drug: Medication-related adverse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication-related adverse events (MRE) in anaesthesia care
Study: 31780140
Drug: Vasoconstrictor agents,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vasoconstrictor agents, benzodiazepines, and neuromuscular blocking agents
Study: 31780255
Drug: Atezolizumab (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (15 mg/kg for patients <18 years, 1200 mg for patients 18-29 years)
Study: 31783773
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol serum levels ≥ 20 mg/L
Study: 31783773
Drug: Certolizumab pegol
Normalized name: Certolizumab Pegol
DrugBank: Certolizumab pegol (DB08904)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Certolizumab pegol serum levels > 40 mg/L
Study: 31783773
Drug: Anti-drug antibodies
Normalized name: Anti-VEGF monoclonal antibody
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anti-drug antibodies detected in serum samples
Study: 31783816
Drug: Precision radiotherapy
Normalized name: Precise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Precision radiotherapy (volumetric modulated arc therapy or stereotactic body radiotherapy) with 18 × 2.33Gy in 3.5 weeks
Study: 31785337
Drug: Postoperative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Postoperative radiation therapy (RT) to at-risk areas in the involved neck (60-66 Gy) and uninvolved neck (54 Gy)
Study: 31785503
Drug: Insulin treatment
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin treatment (monotherapy or combination therapy)
Study: 31785831
Drug: Intrathecal autologous
Normalized name: Autologous cultured fibroblasts
DrugBank: Azficel-T (DB11051)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intrathecal autologous adipose tissue-derived mesenchymal stem cells (AD-MSCs) - 100 million cells infused after a standard lumbar puncture at the L3-4 level, administered 11 months after injury.
Study: 31786124
Drug: Chemoradiotherapy (chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemoradiotherapy (chemotherapy and 55.8 Gy radiotherapy)
Study: 31786124
Drug: Neoadjuvant chemoradiotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemoradiotherapy (chemotherapy and 45 Gy radiotherapy, then surgery and radiotherapy boost)
Study: 31786276
Drug: Intensity-modulated radiotherapy
Normalized name: California intense cedar pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity-modulated radiotherapy (IMRT) using a simultaneous integrated boost technique (60 Gy high dose and 54 Gy low dose in 30 fractions)
Study: 31786971
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for ASCVD
Study: 31787498
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) glibenclamide (BIIB093; glyburide) treatment
Study: 31789931
Drug: Allergen-specific immune
Normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allergen-specific immune signature-guided dietary elimination therapy
Study: 31790766
Drug: Sofosbuvir-based direct-acting
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-based direct-acting antivirals (DAAs)
Study: 31790766
Drug: Sofosbuvir-free direct-acting
Normalized name: Sofosbuvir
DrugBank: Sofosbuvir (DB08934)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Sofosbuvir-free direct-acting antivirals (DAAs)
Study: 31792136
Drug: Antibody blockade
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody blockade of IL12p40
Study: 31793850
Drug: FDG PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: FDG PET/MRI with dedicated liver and rectal MRI
Study: 31793891
Drug: PAGETEX medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals (Metvixia incubation for 30 minutes and 635 nm red light illumination for 2 hours and 30 minutes, total fluence of 12 J/cm²)
Study: 31793891
Drug: PAGETEX medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: PAGETEX medical device with Metvixia, administered in two PDT sessions at 15-day intervals
Study: 31794031
Drug: Support for
Normalized name: GNP Diabetic Support Formula Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Support for HIV infection and substance use treatment
Study: 31794605
Drug: Gender-affirming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-affirming treatment in transgender men (TM)
Study: 31794605
Drug: Gender-affirming treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender-affirming treatment in transgender women (TW)
Study: 31795981
Drug: Mass Testing,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass Testing, Treatment and Tracking (MTTT)
Study: 31796469
Drug: MK-3475 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-3475 (200 mg every 21 days) in combination with BCG
Study: 31796939
Drug: Preoperative chemical
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative chemical vestibular ablation with 0.5 - 1.0 mL of 40 mg/mL nonbuffered gentamicin administered in three intratympanic instillations.